Standigm

company

About

Standigm is an AI-driven workflow drug discovery company that aims to improve the success rates and efficiency of new drug development.

  • 101 - 250

Details

Last Funding Type
Series C
Last Funding Money Raised
$36.41M
Industries
Artificial Intelligence,Biotechnology,Health Care,Machine Learning,Pharmaceutical
Founded date
May 4, 2015
Number Of Employee
101 - 250
Operating Status
Active

Standigm is a workflow AI-driven drug discovery company. Standigm has proprietary AI platforms encompassing novel target identification to lead generation to generate commercially valuable drug pipelines. Founded in 2015, the company has established an early-stage drug discovery workflow AI to generate First-in-Class lead compounds within seven months. Pursuing full-stack, AI-driven industrializing drug discovery, Standigm has achieved the automation of molecular design workflow through DarkMolFactory™, and the automation effort has been expanding to the whole drug discovery process on the basis of Standigm AI platforms, including Standigm ASK™ for target discovery, Standigm BEST™ for lead design, and Standigm Insight™ for drug repurposing.

Funding Rounds

Number of Funding Rounds
Total Funding Amount
2
$46.41M
Standigm has raised a total of $46.41M in funding over 2 rounds. Their latest funding was raised on Jun 30, 2021 from a Series D round.
Announced Date Round Money Raised Number of Investors Lead Investors Post Valuation
Jun 30, 2021 Series D $10M 1 Pavilion Capital Detail
Mar 5, 2021 Series C $36.41M 2 SKS PE Detail

Investors

Number of Lead Investors
Number of Investors
2
3
Standigm is funded by 3 investors. Pavilion Capital and SKS PE are the most recent investors.
Investor Name Lead Investor Funding Round
Pavilion Capital Yes Series D
SKS PE Yes Series C
Asset One Series C